华润医疗(01515)发布公告，自2025年11月7日起，张闯先生获委任为执行董事及总裁;吴新春先生获委任 为执行董事;及于海先生辞任总裁。 ...

（原标题：华润医疗(01515)：张闯获委任为执行董事） 智通财经APP讯，华润医疗(01515)发布公告，自2025年11月7日起，张闯先生获委任为执行董事及总裁; 吴新春先生获委任为执行董事;及于海先生辞任总裁。 ...

格隆汇11月7日丨华润医疗(01515.HK)宣布，自2025年11月7日起：(1)张闯获委任为执行董事及总裁； (2)吴新春获委任为执行董事；及(3)于海辞任总裁。 ...

華 潤 醫 療 控 股 有 限 公 司 （於 開 曼 群 島 註 冊 成 立 之 有 限 責 任 公 司） （股 份 代 號：1515） （「本 公 司」，連 同 其 附 屬 公 司 合 稱「本 集 團」） 提 名 委 員 會 （「委 員 會」） 之 職 權 範 圍 （於2013年11月4日 獲 董 事 會 採 納， 及 經 董 事 會 於2018年11月27日 及2025年11月7日 修 訂） 1. 成 員 2. 秘 書 3. 法 定 人 數、會 議 出 席 情 況 及 決 議 案 – 1 – (c) 委 員 會 於 任 何 會 議 上 之 決 議 案 須 獲 出 席 成 員 所 投 過 半 數 票 數 通 過。 (d) 經 由 全 體 成 員 簽 署 的 書 面 決 議 案 將 為 有 效 及 具 效 力，猶 如 該 決 議 案 已 於 正 式 召 開 及 舉 行 的 委 員 會 會 議 上 通 過。 (a) 每 年 至 少 一 次 檢 討 董 事 會 架 構、規 模、組 成 及 所 需 的 各 種 技 能、 知 識、教 育 背 景、經 驗 及 多 元 性（包 括 性 別 等 方 面）及 協 助 董 事 ...

（於開曼群島註冊成立的有限責任公司） （股份代號：1515） 董事名單及其角色和職能 胡定旭 傅廷美 華潤醫療控股有限公司的董事會（「董事會」）成員載列如下： 執行董事 于海， 董事長 張闖， 總裁 吳新春， 副總裁 楊敏， 首席財務官 非執行董事 葛路 獨立非執行董事 周鵬 羅詠詩 董事會設立三個委員會，即審核委員會、提名委員會及薪酬委員會。各董事會成 員在該等委員會所擔任的職位載列如下。 | | 委員會 | 審核 | 提名 | 薪酬 | | --- | --- | --- | --- | --- | | 董事 | | 委員會 | 委員會 | 委員會 | | 于海 | | | C | | | 張闖 | | | | | | 吳新春 | | | | | | 楊敏 | | | | | | 葛路 | | | | M | | 胡定旭 | | | M | C | | 傅廷美 | | C | | M | | 周鵬 | | M | | | | 羅詠詩 | | M | M | | 附註： C 有關董事委員會之主席 M 有關董事委員會之成員 中國，2025年11月7日 ...

張先生及吳先生的履歷詳情如下： （於開曼群島註冊成立的有限責任公司） （股份代號：1515） 委任執行董事及總裁變更 董 事 會 謹 此 宣 佈 ， 自 2025 年 11 月 7 日 起 ： (1 ) 張 闖 先 生 獲 委 任 為 執 行 董 事 及 總 裁；(2)吳新春先生獲委任為執行董事；及(3)于海先生辭任總裁。 華 潤 醫 療 控 股 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）之 董 事（「 董 事」）會（「董事會」）謹此宣佈，自2025年11月7日起，(1)張闖先生（「張先生」）獲委 任為執行董事及本公司總裁（「總裁」）；及(2)吳新春先生（「吳先生」）獲委任為執行 董事。於張先生獲委任為總裁後於同日起，本公司執行董事、董事長及總裁于海 先生（「于先生」）因本公司的工作安排辭任總裁職務。于先生辭任總裁後，仍繼續 擔任執行董事和董事長。于先生已確認，彼與董事會概無意見分歧，亦無任何有 關彼辭任總裁的事宜須提呈本公司股東（「股東」）及香港聯合交易所有限公司（「聯 交所」）垂注。 董事會藉此衷心感謝于先生擔任總裁期間對本集團作出的寶貴貢獻。 – 1 – ...

截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 公司名稱: 華潤醫療控股有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01515 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 3,040,000,000 | HKD | | 0.00025 | HKD | | 760,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 3,040,000,000 | HKD | | 0.00025 | HKD | | 760,000 | 本月底法定/註冊 ...

Group 1: Heart Disease Medical Devices - Haitong International maintains an "outperform" rating for Xintai Medical, with a target price of HKD 28.94, highlighting its leadership in congenital heart disease intervention devices and a projected revenue growth of 32.4% year-on-year for H1 2025 [1] Group 2: Express Delivery Services - CITIC Securities maintains a "buy" rating for Jitu Express, noting a 23.1% year-on-year increase in parcel volume in Q3, with Southeast Asia's growth rate reaching 78.7%, driven by cost and efficiency advantages [2] - Shenwan Hongyuan also maintains an "accumulate" rating for Jitu Express, reporting a market share increase to 32.8% and a recovery in domestic express delivery prices, despite a downward revision in profit forecasts [3] Group 3: Healthcare and Medical Services - CITIC Jiantou maintains a "buy" rating for China Resources Medical, indicating that while H1 2025 performance may be pressured by declining average medical insurance fees, the company holds a solid regional leadership position [4] - CITIC Jiantou also maintains a "buy" rating for Weitai Medical, projecting a 63.1% year-on-year revenue growth for H1 2025, with significant narrowing of losses and potential for breakeven by year-end [5] Group 4: Consumer Goods and Retail - Guosen Securities maintains an "outperform" rating for Shangmei Co., with a target price of HKD 120.9, emphasizing strong growth in net profit at a compound annual growth rate of 130% from 2022 to 2024 [6] - Huaxin Securities maintains an "accumulate" rating for Nayuki Tea, benefiting from demand catalyzed by Meituan's delivery subsidies and seasonal effects, with improved profitability through product innovation [7] - Huaxin Securities also maintains a "buy" rating for Wugu Mofang, reporting a 14% revenue growth and an 18% net profit increase for H1 2025, driven by strong performance in offline channels [8] Group 5: Food and Beverage - Guangda Securities maintains an "accumulate" rating for Xiaocaiyuan, noting its position as a leading casual dining chain with a customer price range of HKD 50-70, and plans to expand to 1,000 stores by the end of 2026 [10] - Xibu Securities initiates coverage on China Resources Beverages with an "accumulate" rating and a target price of HKD 15, highlighting a market share of 32.7% and improvements in gross margin through increased self-production [11]

Core Viewpoint - Company reported a 9.1% year-on-year decline in revenue for H1 2025, with a 21.8% drop in net profit attributable to shareholders. Excluding compensation received, net profit fell by 57.1%, primarily due to decreased average medical expenses under health insurance and a reduction in IOT business scale [1][2][3] Financial Performance - In H1 2025, the company achieved revenue of 4.525 billion yuan, down 9.1% year-on-year, and a net profit of 374 million yuan, down 26.9%. The net profit attributable to shareholders was 340 million yuan, down 21.8%. Earnings per share (EPS) stood at 0.27 yuan. The board declared an interim dividend of 0.05 yuan per share, unchanged from the previous year [1][2] - The company's own hospitals generated revenue of 4.259 billion yuan in H1 2025, a decrease of 7.4%. While outpatient visits increased by 1.0%, inpatient visits fell by 3.9%. The decline in average medical expenses under health insurance led to a 5.8% drop in both outpatient and inpatient revenue [2] - The gross profit for the hospital business segment was 670 million yuan, down 27.4%, with a gross margin of 15.7%, a decrease of 4.4 percentage points year-on-year. The profit for this segment was 255 million yuan, down 51.1%, indicating that profit decline outpaced revenue decline due to significant gross profit reduction [2][3] Business Development - The company has 103 medical institutions, including 13 tertiary hospitals, 22 secondary hospitals, and 41 primary hospitals as of mid-2025. It is actively responding to external environmental changes and has made progress in business development, enhancing patient experience through various initiatives [2][3] - The overall gross margin for H1 2025 was 15.7%, down from 20.8% in the previous year. The core hospital business gross margin was also 15.7%, reflecting a significant impact on profitability [3] Financial Structure - As of June 30, 2025, the company's leverage ratio (interest-bearing debt/total assets) was 9.9%, down from 10.8% at the end of 2024. Despite having a net current liability of 1.21 billion yuan, the company has approximately 8.02 billion yuan in unused bank credit, indicating a generally stable financial condition [4] - The company expects to maintain steady growth in H2 2025, leveraging its regional leadership in hospitals and ongoing investment in discipline construction [4][5] Future Outlook - Revenue projections for 2025-2027 are estimated at 9 billion yuan, 9.199 billion yuan, and 9.404 billion yuan, with year-on-year changes of -8.67%, +2.21%, and +2.23% respectively. The net profit attributable to shareholders is forecasted at 529 million yuan for both 2025 and 2026, and 556 million yuan for 2027, with corresponding growth rates of -6.49%, 0.03%, and 4.99% [5]

Group 1 - The core viewpoint of the report is that CITIC Construction Investment maintains a "buy" rating for China Resources Medical, projecting revenues of 9 billion yuan, 9.199 billion yuan, and 9.404 billion yuan for 2025-2027, with year-on-year changes of -8.67%, +2.21%, and +2.23% respectively [1] - The expected net profit attributable to shareholders for the same period is 529 million yuan, 529 million yuan, and 556 million yuan, with year-on-year changes of -6.49%, +0.03%, and +4.99% respectively [1] - In the first half of 2025, the company achieved revenues of 4.525 billion yuan, a year-on-year decrease of 9.1%, and a net profit of 374 million yuan, down 26.9% year-on-year [1] Group 2 - The company plans to maintain a mid-term dividend of 0.05 yuan per share, consistent with the same period last year [1] - External factors such as medical insurance payment reform and intensified regional competition are expected to impact the company, but it is anticipated to maintain stable development due to its leading position in the region and ongoing investment in discipline construction [1] - The company will closely monitor the progress of national and local high-quality development plans for state-owned enterprises in the medical sector to seize opportunities in the future consolidation wave of the Chinese healthcare industry [1] Group 3 - The parent company, China Resources Health, owns non-listed medical institutions under the Aerospace Hospital system, which includes Beijing Aerospace General Hospital, Xi'an Aerospace Hospital, and Shaanxi Aerospace Hospital, with a projected revenue scale exceeding 3 billion yuan in 2024 [2] - The group plans to seize opportunities in the capital market to inject quality assets into the listed company, referencing the acquisition of assets from its parent company in 2023 [2] - The company is expected to achieve steady growth in scale through these strategic moves [2]